These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

563 related items for PubMed ID: 24656296

  • 1. ITP and international guidelines: what do we know, what do we need?
    Rodeghiero F, Ruggeri M.
    Presse Med; 2014 Apr; 43(4 Pt 2):e61-7. PubMed ID: 24656296
    [Abstract] [Full Text] [Related]

  • 2. Sequence of treatments for adults with primary immune thrombocytopenia.
    George JN.
    Am J Hematol; 2012 May; 87 Suppl 1():S12-5. PubMed ID: 22389032
    [Abstract] [Full Text] [Related]

  • 3. [Diagnostic approach and treatment of immune thrombocytopenia in adults].
    Kolonić SO, Patekar MB, Milunović V.
    Acta Med Croatica; 2013 Mar; 67(1):3-11. PubMed ID: 24279250
    [Abstract] [Full Text] [Related]

  • 4. Consensus Paper-ICIS Expert Meeting Basel 2009 treatment milestones in immune thrombocytopenia.
    Tamary H, Roganovic J, Chitlur M, Nugent DJ.
    Ann Hematol; 2010 Jul; 89 Suppl 1(Suppl 1):5-10. PubMed ID: 20358200
    [Abstract] [Full Text] [Related]

  • 5. [Immune thrombocytopenias: pathophysiology and treatment].
    Godeau B.
    Bull Acad Natl Med; 2013 Feb; 197(2):407-17. PubMed ID: 24919370
    [Abstract] [Full Text] [Related]

  • 6. Immune thrombocytopenia.
    Bussel J, Cooper N, Boccia R, Zaja F, Newland A.
    Expert Rev Hematol; 2021 Nov; 14(11):1013-1025. PubMed ID: 34720027
    [Abstract] [Full Text] [Related]

  • 7. Management of primary immune thrombocytopenia, 2012: a survey of oklahoma hematologists-oncologists.
    Lu KH, George JN, Vesely SK, Terrell DR.
    Am J Med Sci; 2014 Mar; 347(3):190-4. PubMed ID: 23462246
    [Abstract] [Full Text] [Related]

  • 8. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J, Wall E, Bolster L, Patterson JM, Goodyear MD, Rydz N, Sun HL.
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [Abstract] [Full Text] [Related]

  • 9. Immune thrombocytopenia: no longer 'idiopathic'.
    McCrae K.
    Cleve Clin J Med; 2011 Jun; 78(6):358-73. PubMed ID: 21632906
    [Abstract] [Full Text] [Related]

  • 10. Current and emerging treatments for immune thrombocytopenia.
    Dou X, Yang R.
    Expert Rev Hematol; 2019 Sep; 12(9):723-732. PubMed ID: 31237783
    [Abstract] [Full Text] [Related]

  • 11. Need for an improved vaccination rate in primary immune thrombocytopenia patients exposed to rituximab or splenectomy. A nationwide population-based study in France.
    Moulis G, Lapeyre-Mestre M, Mahévas M, Montastruc JL, Sailler L.
    Am J Hematol; 2015 Apr; 90(4):301-5. PubMed ID: 25557586
    [Abstract] [Full Text] [Related]

  • 12. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ.
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [Abstract] [Full Text] [Related]

  • 13. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: New insights for an old treatment.
    Mageau A, Terriou L, Ebbo M, Souchaud-Debouverie O, Orvain C, Graveleau J, Lega JC, Ruivard M, Viallard JF, Cheze S, Dossier A, Bonnotte B, Perlat A, Gobert D, Costedoat-Chalumeau N, Jeandel PY, Dernoncourt A, Michel M, Godeau B, Comont T.
    Am J Hematol; 2022 Jan 01; 97(1):10-17. PubMed ID: 34661954
    [Abstract] [Full Text] [Related]

  • 14. [Treatment of ITP and AIHA in CVID: A systematic literature review].
    Lacombe V, Lozac'h P, Orvain C, Lavigne C, Miot C, Pellier I, Urbanski G.
    Rev Med Interne; 2019 Aug 01; 40(8):491-500. PubMed ID: 31101329
    [Abstract] [Full Text] [Related]

  • 15. [New treatment methods for autoimmune thrombocytopenia].
    Koene HR.
    Ned Tijdschr Geneeskd; 2007 Nov 24; 151(47):2609-14. PubMed ID: 18161261
    [Abstract] [Full Text] [Related]

  • 16. A critical appraisal of the evidence for the role of splenectomy in adults and children with ITP.
    Rodeghiero F.
    Br J Haematol; 2018 Apr 24; 181(2):183-195. PubMed ID: 29479668
    [Abstract] [Full Text] [Related]

  • 17. Conflicts of interest and clinical recommendations: comparison of two concurrent clinical practice guidelines for primary immune thrombocytopenia developed by different methods.
    George JN, Vesely SK, Woolf SH.
    Am J Med Qual; 2014 Apr 24; 29(1):53-60. PubMed ID: 23550214
    [Abstract] [Full Text] [Related]

  • 18. Current therapies in primary immune thrombocytopenia.
    Pels SG.
    Semin Thromb Hemost; 2011 Sep 24; 37(6):621-30. PubMed ID: 22102265
    [Abstract] [Full Text] [Related]

  • 19. [Current treatment of primary immune thrombocytopenia].
    Lozano ML, Vicente V.
    Med Clin (Barc); 2014 May 06; 142(9):399-405. PubMed ID: 23809409
    [Abstract] [Full Text] [Related]

  • 20. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K, Miyakawa Y, Ikeda S, Sato Y, Takebayashi T.
    BMC Health Serv Res; 2015 Jan 22; 15():2. PubMed ID: 25609557
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.